-+ 0.00%
-+ 0.00%
-+ 0.00%

RBC Capital Maintains Outperform on Cytokinetics, Raises Price Target to $95

Benzinga·12/22/2025 14:24:23
語音播報
RBC Capital analyst Leonid Timashev maintains Cytokinetics (NASDAQ:CYTK) with a Outperform and raises the price target from $87 to $95.